Advertisement
Advertisement
U.S. markets open in 7 hours 46 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Aeglea BioTherapeutics, Inc. (AGLE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
11.33-0.30 (-2.58%)
At close: 03:53PM EDT
11.64 +0.31 (+2.74%)
After hours: 07:27PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Performance Outlook
Previous Close11.63
Open11.34
Bid0.00 x 800
Ask0.00 x 1000
Day's Range11.01 - 12.31
52 Week Range2.66 - 39.00
Volume13,814
Avg. Volume66,745
Market Cap45.861M
Beta (5Y Monthly)2.53
PE Ratio (TTM)N/A
EPS (TTM)-72.16
Earnings DateNov 01, 2023 - Nov 06, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for AGLE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Aeglea BioTherapeutics, Inc.
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
    Rating
    Fair Value
    Economic Moat
    2 years agoMorningstar
View more
  • PR Newswire

    Aeglea BioTherapeutics to Participate in Upcoming September Conference

    Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that management will participate in the Stifel 2023 Immunology & Inflammation Virtual Summit.

  • PR Newswire

    Aeglea BioTherapeutics Announces Reverse Stock Split

    Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced it will effect a reverse stock split of all outstanding shares of Aeglea's common stock at a ratio of 1-for-25. Aeglea expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on September 8, 2023.

  • PR Newswire

    Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones

    Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced the appointment of Scott Burrows, as Chief Financial Officer and Heidy Abreu King-Jones as Chief Legal Officer and Corporate Secretary. Both will report to Cameron Turtle, Chief Operating Officer of Aeglea, and join the Company's leadership team. Aeglea also announced that

Advertisement
Advertisement